| DC10479 |
RX518(CK-101:EGFR-IN-3)
|
RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations. |
| DC1091 |
PF-299804 (Dacomitinib,PF-00299804)
|
PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively. |
| DC7225 |
Pelitinib (EKB-569; WAY-EKB 569)
|
Pelitinib (EKB-569; WAY-EKB 569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. |
| DC11900 |
Lazertinib
|
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations |
| DC2103 |
Gefitinib (ZD1839)
|
Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
| DC3139 |
Erlotinib hydrochloride
|
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
| DC2101 |
Erlotinib free base
|
Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
| DC7106 |
Rociletinib (CO-1686)
|
CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM). |
| DC3138 |
Canertinib dihydrochloride
|
Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. |
| DC8462 |
AZD-9291 mesylate (Osimertinib，Mereletinib)
|
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
